Work

Isatuximab short duration fixed volume infusion combination therapy for relapsed/refractory multiple myeloma (RRMM): phase 1b feasibility/safety study

Year: 2019

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2019.09.466

Authors: Saad Usmani, Chatchada Karanes, William I. Bensinger, Anita D'Souza, Noopur Raje, Sascha Tuchman, Douglas Sborov, Dheepak Kanagavel, Franck Dubin, Frank Campana, Paul G. Richardson

Institutions: Carolinas Healthcare System, Levine Cancer Institute, City Of Hope National Medical Center, City of Hope, Medical College of Wisconsin, Massachusetts General Hospital, University of Utah, Sanofi (France), Harvard University, Dana-Farber Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2980918504

FWCI: 0.303

Cites:

Cited by: 2

Related to: 10